{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:50:52Z","timestamp":1781877052811,"version":"3.54.5"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Allogeneic hematopoietic stem cell transplantation (allo\u2010HSCT) remains the only potentially curative therapy for many patients with high\u2010risk myeloid neoplasms, yet relapse and transplant\u2010related toxicity continue to limit durable benefit. Venetoclax (VEN), a selective BCL\u20102 inhibitor, provides a biologically compelling strategy for conditioning augmentation through chemotherapy sensitization and potential lowering of host immune resistance to engraftment. We performed a hybrid scoping review and evidence\u2010mapping analysis to summarize published clinical experience and the active investigational landscape of VEN\u2010containing conditioning or sequential regimens prior to allo\u2010HSCT. Eighteen studies (20 reports) met the inclusion criteria, including nine published cohorts comprising 238 patients and 11 ongoing clinical trials. Reported platforms were heterogeneous, spanning reduced\u2010intensity, myeloablative, and sequential approaches. Engraftment and graft\u2010versus\u2010host disease outcomes were generally comparable to expected benchmarks, although available data remain preliminary and non\u2010randomized, underscoring that the primary aim of this scoping review is to map existing evidence and ongoing trials rather than to inform clinical practice or guideline recommendations.<\/jats:p>","DOI":"10.1111\/ejh.70189","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:36:29Z","timestamp":1775018189000},"page":"117-131","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax\u2010Integrated Conditioning Strategies Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Myeloid Neoplasms: A Scoping Review of Emerging Evidence"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0622-8455","authenticated-orcid":false,"given":"Mohammed","family":"Abdulgayoom","sequence":"first","affiliation":[{"name":"Haematology\/BMT Department National Center for Cancer Care and Research, HMC  Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaal","family":"Gulied","sequence":"additional","affiliation":[{"name":"Pharmacy Department National Center for Cancer Care and Research, HMC  Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4454-5307","authenticated-orcid":false,"given":"Awni","family":"Alshurafa","sequence":"additional","affiliation":[{"name":"Haematology\/BMT Department National Center for Cancer Care and Research, HMC  Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6118-3988","authenticated-orcid":false,"given":"Shehab F.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Haematology\/BMT Department National Center for Cancer Care and Research, HMC  Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[{"name":"Haematology\/BMT Department National Center for Cancer Care and Research, HMC  Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afraa","family":"Fadul","sequence":"additional","affiliation":[{"name":"Haematology\/BMT Department National Center for Cancer Care and Research, HMC  Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01691-w"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028617"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.10.32"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.10.002"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60237-3"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010484"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000567"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28193"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.749094"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-018-0228-y"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005566"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030532"},{"key":"e_1_2_13_14_1","unstructured":"U.Popat R. L.Bassett A. M.Alousi et\u00a0al. Myeloablative Fractionated Busulfan Fludarabine Cladribine Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High\u2010Risk AML\/MDS: A Phase 2 Trial."},{"key":"e_1_2_13_15_1","unstructured":"U. R.Popat R. S.Mehta R.Bassett et\u00a0al. Myeloablative Fractionated Busulfan Conditioning Regimen With Venetoclax in Patients With AML\/MDS: Prospective Phase II Clinical Trial."},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2164610"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05500-2"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207083"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1530852"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000526697"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.83"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700603"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705878"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0247"},{"issue":"6","key":"e_1_2_13_25_1","first-page":"1695","article-title":"Chronic Graft\u2010Versus\u2010Host Disease After Allogeneic Blood Stem Cell Transplantation","volume":"98","author":"Przepiorka D.","year":"2001","journal-title":"Blood, the Journal of the American Society of Hematology"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03165241"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.043810"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70189","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70189","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:54:14Z","timestamp":1781873654000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/ejh.70189"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70189","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"2026-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}